- Q1 total revenue of $49.3 million, a YoY increase of 95.3%.
- Q1 RHA® Collection revenue of $30.3 million, a YOY increase of 45.3%.
- Q1 DAXXIFY® revenue of $15.4 million, driven by PrevU. | May 9, 2023
Received FDA approval for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar linesQ3 total revenue of $29.0 million, a YoY increase of 47% with RHA® Collection revenue of $26.1 million, a YoY increase of 43%Aesthetic accounts across products and services totaled over 4,500 at quarter-en.